DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Cotrifazid Safety and Efficacy Against Malaria

Information source: Policlinique Médicale Universitaire
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Clinical Malaria

Intervention: Cotrifazid vs mefloquine or quinine+SP (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Policlinique Médicale Universitaire

Official(s) and/or principal investigator(s):
Blaise Genton, MD, PhD, Principal Investigator, Affiliation: Swiss Tropical & Public Health Institute


The purpose of this study was to assess the safety and efficacy of Cotrifazid to treat uncomplicated resistant malaria and to compare the outcome with mefloquine or quinine+sulfadoxine/pyrimethamine (SP)

Clinical Details

Official title: A Randomised Safety and Efficacy Trial of Rifampicin/Cotrimoxazole/Isoniazid Versus Mefloquine or Quinine+SP Against Resistant Malaria in Papua New Guinea

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Clinical treatment failure rate on day 14.

Incidence of adverse events.

Secondary outcome:

Parasitological failure rate on day 14

Fever clearance time

Parasite clearance time

Symptoms clearance time

Occurrence of complications

Detailed description: Design: Open-label, block-randomised, comparative, multicentric trial. Setting: Four primary care health facilities, two in urban and two in rural areas of Madang and East Sepik Province, Papua New Guinea. Participants: Patients of all ages with recurrent uncomplicated malaria Intervention: Random assignment to receive either Cotrifazid, mefloquine or the standard treatment of quinine+sulfadoxine/pyrimethamine (SP). Outcome measures: Incidence of clinical and laboratory adverse events; rate of clinical and/or parasitological failure at day 14


Minimum age: 6 Months. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: All subjects > 6 months of age who presented at the centres and who were diagnosed with malaria (history of fever, OptiMAL® test positive, no other major symptom) and who had already been treated for malaria in the 28 days before, could be included in the study, if the subject or legal guardian (for children) gave informed consent and if the clinician in charge would have given the standard treatment for resistant malaria independent of the

study -

Exclusion Criteria: A subject was not to be included if the clinician preferred to use quinine for whatever reason, if the patient had one of the symptoms or signs of complicated or severe malaria (i. e. history of recent convulsion, any neurological sign or impairment of consciousness, heavy vomiting, haemoglobinuria, respiratory distress, bleeding, circulatory collapse, shock, jaundice, haemoglobin < 5 g/dl), had contra-indications for mefloquine (history of psychiatric disorder, epilepsy), or was pregnant.


Locations and Contacts

Health centers, Madang and Maprik, Madang and East Sepik Province, Papua New Guinea
Additional Information

Starting date: April 2000
Last updated: May 5, 2006

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017